Testing dapagliflozin for pulmonary hypertension
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether the diabetes drug dapagliflozin can help people with pulmonary hypertension (high blood pressure in the lungs). The goal is to see if it improves symptoms and heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pulmonary hypertension, confirmed by right heart catheterization or suggested by an echocardiogram.
- Your blood pressure is not too low (systolic blood pressure 95 mmHg or higher).
- Your kidneys are working well (eGFR above 30 and potassium level normal).
- You do not have other serious heart problems like valve disease, blocked arteries, or recent blood clots in the lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
This trial tests if adding dapagliflozin (a diabetes drug) helps control heart rhythm in people recently diagnosed with atrial fibrillation. It's for those who haven't tried rhythm control treatments before.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.